GSK-208136/039

Study Sponsor: GSK

Study Title

Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®.

Medicine or Vaccine (generic name)

Combined Measles, Mumps, Rubella, Varicella Vaccine

Sponsor Identification Number

208136/039

Trial Registry Identification Number(#'s)

NCT00406211

Medical Condition

Measles; Mumps; Rubella; Varicella

Phase

Phase 3

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=208136/039

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00406211

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a Year 1 follow-up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided.

Date Added to this Site

February 2015